The utility of the HFA-ICOS cardiotoxicity risk assessment tool for HER2-targeted cancer therapies in patients with metastatic breast cancer: from theory to clinical practice.

Back

ESC Professional Premium Access

The utility of the HFA-ICOS cardiotoxicity risk assessment tool for HER2-targeted cancer therapies in patients with metastatic breast cancer: from theory to clinical practice.

Session: Cardiotoxicity: mechanisms, biomarkers, and treatment

Topic: Cardio-Oncology

Speaker: Doctor D. Leocachin Parra (Mexico City, MX)

Event: ESC Congress 2023

Congress Presentation

About the speaker

Doctor Daniela Leticia Leocachin Parra

UMAE Hospital de Cardiologia CMN Siglo XXI IMSS, Mexico City (Mexico)

2 presentations

1 follower

7 more presentations in this session

The potentially protective effect of dapagliflozin on the development of cardiotoxicity in cancer patients

Speaker: Doctor S. Maragkoudakis (Chania, GR)

SGLT2 i Dapagliflozin reduces NF-kB expression in heart and kydneys of preclinical models exposed to doxorubicin through MYd-88 and NLRP3 pathways: an hystological study

Speaker: Doctor N. Maurea (Naples, IT)

SGLT2i Dapagliflozin decreases NLRP3, IL-1 and PCSK9 expression in preclinical models of short-term doxorubicin cardiotoxicity

Speaker: Doctor N. Maurea (Naples, IT)

The use of high sensitivity troponin T as a biomarker of anthracycline cardiotoxicity

Speaker: Doctor C. Bannister (London, GB)

Differences in the prevalence of cardiovascular toxicity in a cohort of female breast cancer patients according to the different cardiotoxicity definitions

Speaker: Doctor J. Herrera (Cordoba, ES)

Access the full session

Cardiotoxicity: mechanisms, biomarkers, and treatment

Speakers: Doctor D. Leocachin Parra, Doctor S. Maragkoudakis, Doctor N. Maurea, Doctor N. Maurea, Doctor C. Bannister...

Access

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

The utility of the HFA-ICOS cardiotoxicity risk assessment tool for HER2-targeted cancer therapies in patients with metastatic breast cancer: from theory to clinical practice.

About the speaker

Doctor Daniela Leticia Leocachin Parra

7 more presentations in this session

The potentially protective effect of dapagliflozin on the development of cardiotoxicity in cancer patients

SGLT2 i Dapagliflozin reduces NF-kB expression in heart and kydneys of preclinical models exposed to doxorubicin through MYd-88 and NLRP3 pathways: an hystological study

SGLT2i Dapagliflozin decreases NLRP3, IL-1 and PCSK9 expression in preclinical models of short-term doxorubicin cardiotoxicity

The use of high sensitivity troponin T as a biomarker of anthracycline cardiotoxicity

Differences in the prevalence of cardiovascular toxicity in a cohort of female breast cancer patients according to the different cardiotoxicity definitions

Access the full session

Cardiotoxicity: mechanisms, biomarkers, and treatment

About the event

ESC Congress 2023

ESC 365 is supported by